NasdaqGS:CABABiotechs
Assessing Cabaletta Bio (CABA) Valuation After FDA Clearance For Automated CAR T Manufacturing
Cabaletta Bio (CABA) is back in focus after Cellares received FDA clearance for an IND amendment supporting automated manufacturing and quality testing of Cabaletta’s investigational CAR T therapy, rese cel, using Cell Shuttle and Cell Q platforms.
See our latest analysis for Cabaletta Bio.
The FDA clearance news arrives after a sharp shift in sentiment, with Cabaletta Bio’s 7 day share price return of 44.55% and 30 day return of 45.21% contrasting with a 3 year total shareholder return...